Why Your Data Integrity Depends on GAMP 5

Why GAMP 5 Data Integrity Is the Foundation of Pharmaceutical Compliance

GAMP 5 data integrity is the set of principles and practices that ensure every data record generated by a computerized pharmaceutical system is complete, accurate, and trustworthy from creation through retirement.

Here is a quick answer to what GAMP 5 data integrity requires:

GAMP 5 Data Integrity Element What It Means in Practice Risk-based validation Focus testing effort where patient safety risk is highest ALCOA+ compliance Data must be Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available System lifecycle controls Data integrity is designed in from concept to retirement, not bolted on afterward Audit trails All changes to critical records are captured automatically and reviewable Supplier oversight Vendor documentation and quality systems are evaluated as part of validation Regulatory alignment Controls satisfy FDA 21 CFR Part 11, EU GMP Annex 11, and ICH guidelines

If data integrity fails, the consequences are severe. An analysis of 300 FDA warning letters found that poor documentation practices were among the most common violations cited. These are not just paperwork problems. Unreliable data can delay drug approvals, trigger product recalls, and — most critically — put patients at risk.

The pharmaceutical industry has long recognized that computerized systems should never reduce the quality, safety, or control of a product compared to the manual processes they replace. That principle is exactly what GAMP 5 was built to protect.

Yet for many validation managers, achieving consistent data integrity across complex, rapidly evolving system landscapes — legacy platforms, cloud migrations, AI tools, agile-developed software — remains one of the hardest operational challenges in the business.

I'm Stephen Ferrell, Chief Product Officer at Valkit.ai and a contributing author to the GAMP 5 Second Edition, with over two decades of hands-on experience guiding pharmaceutical, biotech, and medical device organizations through the nuanced expectations of global regulators on GAMP 5 data integrity. As Chair of GAMP Americas and a member of the ISPE GAMP Global Steering Committee, I have helped shape how the industry interprets and operationalizes risk-based validation at scale. In this guide, I will walk you through everything you need to know — from core principles to real-world case studies — so you can build a data integrity program that holds up under inspection and drives genuine efficiency.